Risk Factors of the Invasive Breast Cancer Locoregional Recurrence.
BACKGROUND
The aim of the research was to estimate the frequency of the locoregional breast cancer recurrence appearance, the recurrence-free period continuance, and the 3- and 5-year survival depending on the scope of the surgical intervention, menstrual profile, and histological and molecular-biologic characteristics of the primary tumor.


METHODS
Among 218 patients with a breast cancer, 99 patients had breast-conserving surgery (BCS) and 119 underwent radical mastectomy (RME); all patients had regional lymphatic nodes dissection. The size and the primary tumor differentiation degree, metastasis presence in the regional lymph nodes, ER expression, PR, and Her/2neu were assessed as the prognostics factors.


RESULTS
It was defined that the locoregional recurrence appearance frequency in patients with BCS turned out to be 13%, and in patients after RME it turned out to be 9%; the recurrence-free period continuance was 53 ± 8 months and 56 ± 10 months, respectively.


CONCLUSIONS
The locoregional cancer recurrence frequency is higher in women with the menstrual function being preserved at the moment of the primary tumor detection than in postmenopausal patients and also in patients having the hyperexpression of the Her/2neu. The ipsilateral cancer recurrence decreases the 3-year survival by 7,1% and the 5-year one by 20,3%, respectively.
Department of Oncology, National Medical University, 13 Boulevard Shevchenko, Kiev 01030, Ukraine.
R V
RV
Liubota
Department of Oncology, National Medical University, 13 Boulevard Shevchenko, Kiev 01030, Ukraine.
A S
AS
Zotov
Department of Oncology, National Medical University, 13 Boulevard Shevchenko, Kiev 01030, Ukraine.
R I
RI
Vereshchako
Kiev Oncology Municipal Centre, Kiev, Ukraine.
I I
II
Liubota
Department of Oncology, National Medical University, 13 Boulevard Shevchenko, Kiev 01030, Ukraine.
V V
VV
Zaychuk
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D015412:Mastectomy, Segmental; D008597:Menstrual Cycle; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000473:pathology* / Q000532:radiotherapy; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000235:genetics; D012307:Risk Factors
D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human